Institutional Ownership
Nuvectis Pharma Inc
CUSIP 67080T108COMNVCTQ1 2026
13D / 13G Filings
12
Schedule 13D/13G on record
Beneficial Filers
6
Distinct reporting persons
Largest Stake
21.5%
Max % of class reported
Institutional Holders
58
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
12 filings · latest Nov 5, 2024
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Nov 5, 2024 | Pontifax Management 4 G.P. (2015) Ltd. | 13G/A | 1.5% | 288.9K | SEC |
| 2 | Feb 28, 2024 | Mosseri Marlio Charles | 13G/A | 15.0% | 2.60M | SEC |
| 3 | Feb 6, 2024 | Pontifax Management 4 G.P. (2015) Ltd. | 13G | 5.3% | 917.4K | SEC |
| 4 | Feb 1, 2024 | Poradosu Enrique | 13G/A | 8.7% | 1.50M | SEC |
| 5 | Feb 1, 2024 | Shemesh Shay | 13G/A | 8.6% | 1.49M | SEC |
| 6 | Jan 31, 2024 | Peters Thomas Phineas | 13G/A | 5.2% | 908.5K | SEC |
| 7 | Apr 3, 2023 | Peters Thomas Phineas | 13G | 6.4% | 947.7K | SEC |
| 8 | Feb 13, 2023 | Shemesh Shay | 13G | 8.2% | 1.21M | SEC |
| 9 | Feb 13, 2023 | Poradosu Enrique | 13G | 8.3% | 1.22M | SEC |
| 10 | Jan 9, 2023 | Mosseri Marlio Charles | 13G/A | 16.3% | 2.38M | SEC |
2 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Nuvectis Pharma Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Blackrock, Inc. | 764.4K | $5.91M |
| 2 | Iridian Asset Management LLC/Ct | 651.8K | $5.04M |
| 3 | Occam Crest Management LP | 407.1K | $3.15M |
| 4 | Geode Capital Management, LLC | 384.1K | $2.97M |
| 5 | Baldwin Wealth Partners LLC/Ma | 378.6K | $2.93M |
| 6 | State Street Corp | 166.5K | $1.29M |
| 7 | Northern Trust Corp | 124.2K | $960.2K |
| 8 | Susquehanna International Group, LLP | 105.3K | $813.9K |
| 9 | Citadel Advisors LLC | 78.4K | $606.2K |
| 10 | Oppenheimer & Co Inc | 73.6K | $568.7K |